SCHEMBL4052035

SCHEMBL4052035

Cc1c(OC(C)C)cccc1-c1nc2ncc(-c3ccco3)cc2[nH]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKE Q14164 1/20 0.38
TBK1 Q9UHD2 1/20 0.38
PDE5A O76074 7/20 0.36
PDE4A P27815 2/20 0.36
PDE4B Q07343 2/20 0.36
PDE4C Q08493 2/20 0.36
PDE4D Q08499 2/20 0.36
PDE10A Q9Y233 1/20 0.36
GUSB P08236 1/20 0.36
SMPD3 Q9NY59 1/20 0.35
AURKA O14965 4/20 0.35
PAK4 O96013 1/20 0.33
PTGES O14684 1/20 0.33
MEN1 O00255 1/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
MAPT P10636 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4062770 0.85 PDE5A (0.42) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL13608620 0.84 AXL (0.37) PDE5APDE4CPDE10ASMPD3MEN1
SCHEMBL4052773 0.82 SCD (0.48) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL4056606 0.82 IKBKE (0.46) IKBKETBK1SMPD3AURKAGABRA1
SCHEMBL4056063 0.81 PDE5A (0.55) IKBKETBK1PDE5APDE4APDE4B
SCHEMBL4053678 0.81 SCD (0.40) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL4058830 0.80 PAK4 (0.49) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL4060354 0.76 SCD (0.48) IKBKETBK1PDE10AGUSBPTGES
SCHEMBL4060508 0.76 PTGES (0.45) IKBKETBK1PDE10ASMPD3AURKA
SCHEMBL4059101 0.74 IKBKE (0.43) IKBKETBK1SMPD3AURKAGABRP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B IKBKE 129/4885TBK1 1212/4885PDE5A 2762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.